BENLYSTA: 7 years in-market experience1
Adverse reactions in ≥3% of patients receiving BENLYSTA 10 mg/kg + standard therapy and ≥1% more frequently than in those receiving placebo + standard therapy in the 52-week Phase II trial, BLISS-52, and BLISS-761
|Preferred Term||BENLYSTA 10 mg/kg +
|Placebo + Standard Therapy
|Pain in extremity||6||4|
The safety profile for BENLYSTA SC + standard therapy was consistent with that of BENLYSTA IV + standard therapy, with the exception of local injection site reactions.
Injection site reactions occurred in 6.1% of patients receiving BENLYSTA SC + standard therapy and in 2.5% of patients receiving placebo + standard therapy, respectively. The majority (94%) did not necessitate discontinuation of treatment.
Adverse reaction rates observed in clinical studies may not predict those observed in clinical practice.
831318R0 February 2018